Biotechnology

Innovent Announces the NMPA Granted New Indication Approval for BYVASDA® (Bevacizumab Biosimilar) for the Treatment of Adult Recurrent Glioblastoma

SAN FRANCISCO and SUZHOU, China, Dec. 28, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...

2020-12-28 08:00 7787

Arctic Vision obtains the first IND approval for the treatment of UME in China, Suprachoroidal space (SCS) injection potentially brings more benefits to patients

SHANGHAI, Dec. 25, 2020 /PRNewswire/ -- Arctic Vision, a China-based clinical-stage ophthalmology company with a leading portfolio of breakthrough technologies, announced on December 24th the clearance of the Investigational New Drug (IND) for Phase III trial of ARVN001 (triamcinolone acetonide s...

2020-12-25 21:00 3202

INOVIO Announces Publication of Phase 1 Data from its COVID-19 DNA Vaccine Candidate, INO-4800 in The Lancet's EClinicalMedicine

Peer-reviewed Phase 1 data shows INO-4800 to be immunogenic in 100% of subjects, inducing neutralizing antibody and/or T cell responses INO-4800 demonstrates favorable safety and tolerability, with no serious adverse events reported Offers best-in-class thermostability, including a five-year pro...

2020-12-24 23:12 6924

LycovaryTM Daily provides anti-ageing oxygenation of the ovaries to help women with PMS, painful periods and comfortable menopause transition

CAMBRIDGE, England, Dec. 24, 2020 /PRNewswire/ -- Cambridge Diagnostic Imaging, CaDi, (cadifamily.com ) is launching LycovaryTM Daily, a new generation of food supplement for ovarian health in the family of oxygenation products. It provides clinically validated and...

2020-12-24 08:00 3153

I-Mab Announces Upcoming Participation at January Conferences

SHANGHAI and GAITHERSBURG, Md., Dec. 23, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in Januar...

2020-12-23 21:00 5609

Hyundai Bioscience Develops Injection Drug for Potential Treatment of Severe Cases of COVID-19

SEOUL, South Korea, Dec. 22, 2020 /PRNewswire/ -- Hyundai Bioscience (KOSDAQ symbol: 048410) announced on the 23rd, December 2020, that CNPharm, its major shareholding bio tech company, has succeeded in developing 'Poly-COV01,' an injection drug for thepotential treatment of patients with severe ...

2020-12-23 10:09 1439

Transcenta Closes $105 Million in Crossover Financing

HONG KONG and SUZHOU, China, and HANGZHOU, China, Dec. 23, 2020 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta"), a global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announces today the complet...

2020-12-23 08:00 3717

RedHill's Phase 2/3 COVID-19 Study of Opaganib Passes Second DSMB with Unanimous Recommendation to Continue

Independent DSMB unanimously recommends continuation of the global Phase 2/3 study of orally-administered opaganib in severe COVID-19 based on review of unblinded safety data from 155 treated patients Top-line data from the 270-patient global Phase 2/3 COVID-19 study expected Q1/2021 Top-line d...

2020-12-22 20:38 4174

Origin Agritech Comments on Recent Regulatory Developments in China and Updates Shareholders on its Pipeline of Traits

BEIJING, Dec. 22, 2020 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), an agriculture technology company, today is updating shareholders on recent developments out ofChina regarding the path to GMO commercialization in the country and also on the status of the app...

2020-12-22 20:30 5164

Ascentage Pharma's Licensee UNITY Biotechnology Announces Milestone Reached in Clinical Development of Treatments for Age-Related Disease, Leading to Milestone Payment

SUZHOU, China and ROCKVILLE, Md., Dec. 22, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its licensee, UNITY Bi...

2020-12-22 18:29 1622

Alterity and UniQuest partner to reverse bacterial resistance to antibiotics

MELBOURNE, Australia, Dec. 21, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced it has been granted a licence by UniQuest, the commercialisation company of The University of Queensland (UQ), to novel zinc ionophore technology to ...

2020-12-22 05:42 5519

Pierre Fabre Selects AGC Biologics as CDMO to manufacture the orphan drug ER-004

SEATTLE, Dec. 21, 2020 /PRNewswire/ -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced its partnership with Laboratoire Pierre Fabre to manufacture ER-004 – an intra-amniotic drug that will pioneer the treatment of a rare and...

2020-12-21 23:00 1417

Pierre Fabre Selects AGC Biologics as CDMO to manufacture the orphan drug ER-004

SEATTLE, Dec. 21, 2020 /PRNewswire/ -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced its partnership with Laboratoire Pierre Fabre to manufacture ER-004 – an intra-amniotic drug that will pioneer the treatment of a rare and...

2020-12-21 23:00 2554

LT1001 (Naldebain(R)), an Extended-Release Analgesic Injection, Received Its Second Approval from Singapore's HSA

TAIPEI, Dec. 21, 2020 /PRNewswire/ -- Lumosa Therapeutics is pleased to announce the market approval of LT1001 (Naldebain®), an extended-release analgesic injection, fromSingapore's Health Science Agency (HSA). HSA is regarded as one of the regulatory reference countries in the world. The approv...

2020-12-21 22:08 1690

WuXi Biologics to Acquire Drug Substance Facility in Wuppertal, Germany from Bayer

* The DS facility (MFG19) with 3x1000L perfusion and 6x2000L fed-batch capacity for vaccines and biologics is expected to be GMP ready in late 2021 * Complements WuXi Biologics' existing DP capacity in Germany * Capacity expansion allows WuXi Biologics to meet growing client demand worldwide...

2020-12-21 21:02 1843

Longevity Acquisition Corporation Announces 4D pharma Joining Landmark Parkinson's Progression Markers Initiative

NEW YORK, Dec. 21, 2020 /PRNewswire/ -- Longevity Acquisition Corporation (NASDAQ: LOAC) (the "Company"), a publicly-traded special purpose acquisition company, announced today that onDecember 18, 2020, 4D pharma plc (AIM: DDDD) ("4D pharma"), a pharmaceutical company leading the development of L...

2020-12-21 21:00 10685

Thermo Scientific Tundra Cryo-TEM Democratizes Cryo-Electron Microscopy, Extends to Users of Any Experience Level

New instrument overcomes cryo-EM barriers, implements artificial intelligence to deliver unparalleled ease-of-use at an affordable price HILLSBORO, Ore., Dec. 21, 2020 /PRNewswire/ -- Thermo Fisher Scientific, the world leader in serving science, today announced the new Thermo Scientific Tundra ...

2020-12-21 07:00 1796

Teijin Pharma and TransThera Biosciences Form Strategic R&D Collaboration

TOKYO and NANJING, China, Dec. 18, 2020 /PRNewswire/ -- Teijin Pharma Limited  ("Teijin Pharma"), the core company of the Teijin Group 's healthcare business headquartered in Tokyo, Japan, and TransThera Biosciences Co. Ltd. ("TransThera"),...

2020-12-18 23:30 3234

Occlutech's Atrial Flow Regulator (AFR) Receives U.S. FDA Breakthrough Device Designation

SCHAFFHAUSEN, Switzerland, Dec. 18, 2020 /PRNewswire/ -- Occlutech, a privately-held company, announced today that the US Food and Drug Administration (FDA) has granted the company a Breakthrough Device designation for its first-in-class, implantable Atrial Flow Regulator (AFR) for Pulmonary Art...

2020-12-18 21:29 3890

Research on preventative nasal spray, which protects against COVID-19 and common cold, published in leading peer-reviewed academic journals

* Research on preventative COVID-19 nasal spray published in prestigious, peer-reviewed academic journals: EBioMedicine and the European Respiratory Journal * Novel therapy developed by Australian biotech company, Ena Respiratory, shown in animal study to reduce COVID-19 virus levels in the n...

2020-12-18 06:52 1696
1 ... 217218219220221222223 ... 275

Week's Top Stories